Systematic Comorbidity Screening: The Septad Framework
ME/CFS patients frequently present with a cluster of interrelated comorbidities that require distinct treatment approaches. The “Septad” framework (Section Prospective Phenotyping as Harm Reduction) organizes seven conditions that commonly co-occur. Systematic screening can identify treatable contributors to symptom burden.
1 The Seven Septad Components
- Mast Cell Activation Syndrome (MCAS): See Section tVNS Caution in Severe ME/CFS for screening and treatment
- Ehlers-Danlos Syndrome (EDS) / Hypermobility: Joint hypermobility, subluxations, chronic pain
- Dysautonomia / POTS: Orthostatic intolerance (Section Sports-Adapted Pacing: Unresolved Evidence Gaps)
- Autoimmunity: Subclinical or overt autoimmune markers
- Chronic Infection: Viral reactivation (EBV, HHV-6), tick-borne infections
- Small Fiber Neuropathy (SFN): Pain, paresthesias, autonomic symptoms
- GI Dysmotility: Gastroparesis, SIBO, malabsorption
2 Screening Recommendations for Mild-Moderate Cases
EDS / Hypermobility Screening. Screen all ME/CFS patients for hypermobility using the Beighton score. If Beighton score \(\geq\) 5/9 or clinical features suggest EDS:
- Physical therapy referral: Hypermobility-aware PT for joint stabilization
- Avoid overextension: Joints at risk for subluxation and chronic instability
- Consider genetics referral: For formal EDS typing if features suggest vascular or classical type
- Monitor for progression: Hypermobile patients may develop additional complications over time
Craniocervical Instability (CCI) Awareness. CCI is not part of the original Septad but occurs in hypermobile patients and can cause ME/CFS-like symptoms (fatigue, cognitive dysfunction, autonomic dysfunction). A specialized clinic study found high prevalence of structural abnormalities (80% with craniocervical obstructions) in ME/CFS patients, predominantly hypermobile (Bragée et al. 2020); however, these findings require replication in unselected populations (see Section Prospective Phenotyping as Harm Reduction for detailed evidence and caveats). Consider CCI evaluation if:
- Confirmed EDS/hypermobility PLUS
- Symptoms worse with neck position changes, or
- Occipital headaches, or
- Symptoms suggestive of brainstem compression (dysphagia, facial numbness, gait instability)
Evaluation: Upright MRI preferred over supine (dynamic instability may not appear supine); reference ranges for measurements are available (Nicholson et al. 2023). Specialist referral (neurosurgeon with CCI expertise) if clinical suspicion high. See Lohkamp et al. (Lohkamp, Marathe, and Fehlings 2022) for diagnostic criteria review.
CCI is uncommon even in hypermobile ME/CFS patients. However, it represents a structural, potentially treatable cause of symptoms. Conservative management (physical therapy (Russek et al. 2023), cervical collar) is first-line; surgery shows 60–80% improvement in properly selected cases but carries significant complication rates (19%) (Henderson et al. 2024). Do not pursue CCI workup unless hypermobility is present and symptoms are positionally related.
Small Fiber Neuropathy Screening. Consider SFN testing if:
- Burning pain, paresthesias, or allodynia
- Symptoms in stocking-glove distribution
- Autonomic symptoms (sweating abnormalities, GI dysmotility, orthostatic intolerance)
Evaluation: Skin punch biopsy (intraepidermal nerve fiber density) is gold standard. Sudomotor function testing also useful.
Autoimmune Screening. Consider autoimmune workup if:
- Family history of autoimmune disease
- Symptoms suggesting specific autoimmune conditions
- Unexplained inflammatory markers
Basic panel: ANA, ENA panel, RF, anti-CCP, TPO antibodies, anti-gliadin/tTG.
Chronic Infection Evaluation. Consider viral reactivation workup if post-infectious onset or ongoing immune activation:
- EBV: VCA IgG, EBNA IgG, EA IgG (EA elevation suggests reactivation)
- CMV, HHV-6: IgG levels
- Tick-borne: Lyme and co-infections if exposure history
GI Dysmotility Screening. Screen for SIBO and gastroparesis if:
- Bloating, early satiety, nausea, constipation alternating with diarrhea
- Food intolerances or malabsorption symptoms
Testing: Hydrogen/methane breath test for SIBO; gastric emptying study if gastroparesis suspected.
3 Treatment Sequencing
Based on clinical experience rather than validated research, Kaufman proposes addressing mast cell activation syndrome (MCAS) before other Septad components, on the rationale that mast cell stabilization may reduce interconnected symptom burden across multiple domains. This sequencing has not been tested in controlled studies.
The Septad is a clinical framework based on expert observation, not a validated research model. Systematic prevalence data for each component in ME/CFS populations is lacking. Use for organizing comorbidity screening, not as diagnostic criteria for ME/CFS itself. PEM remains the hallmark diagnostic feature (Section Prospective Phenotyping as Harm Reduction).